1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Anthrax Globally
4.2.2 Rising Government Vaccination Programs
4.2.3 Increased Consumption of Undercooked/Raw Meat
4.3 Market Restraints
4.3.1 Lack of Awareness for Diagnostic Test of Target Disease
4.3.2 High Cost of Vaccine
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value- USD)
5.1 By Vaccine Type
5.1.1 Cell Free PA Vaccine
5.1.1.1 Anthrax Vaccine Absorbed (AVA)
5.1.1.2 Anthrax Vaccine Precipitated (AVP)
5.1.2 Live Attenuated Vaccine
5.2 By Applications
5.2.1 Animal Use
5.2.2 Human Use
5.3 By Distribution Channel
5.3.1 Hospitals
5.3.2 Pharmacies
5.3.3 Other Distribution Channels
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Emergent Bio Solutions
6.1.2 Altimmune (Pharmathene Inc.)
6.1.3 Proton Biopharma Ltd
6.1.4 Colondo Serum Company
6.1.5 Merck Co, Inc. (MSD Animal Health)
6.1.6 Bayer AG
6.1.7 Zoetis Inc.
6.1.8 Indian Immunologics
6.1.9 Agrovet
6.1.10 Biogenesis Bago
6.1.11 Tiankang

7 MARKET OPPORTUNITIES AND FUTURE TRENDS